We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...

While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

We recently published a list of 10 Magnificent Dividend Growth Stocks to Invest In. In this article, we are going to take a ...

AbbVie (ABBV) closed the latest trading day at $213.59, indicating a -1.42% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.76% for the day.

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...